Ascentage Pharma Group International American Depository Shares (AAPG) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Omeros (OMER) has outperformed Ascentage Pharma Group International American Depository Shares (AAPG) over the past year, gaining 335.5% versus a loss of 63.8%. Omeros is the larger company by market cap ($1.38 billion vs $1.36 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AAPG | OMER |
|---|---|---|
| Share price | $14.55 | $19.12 |
| Market cap | $1.36B | $1.38B |
| 1-day change | -4.09% | +1.97% |
| YTD return | -44.55% | +11.29% |
| 1-year return | -63.83% | +335.54% |
| 5-year return | — | +147.35% |
| P/E ratio (TTM) | — | 15.67 |
| Forward P/E | — | 15.54 |
| EPS (TTM) | $-2.26 | $1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $38.58 | $21.24 |
| 52-week low | $14.46 | $4.06 |
| Distance from 52-week high | -62.29% | -9.98% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +223.92% | +43.83% |
| Average volume | 6.33K | 1.74M |
| Shares outstanding | 93.39M | 72.39M |
| Employees | 828 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OMER has outperformed AAPG by 399.4 percentage points over the past year.
About Ascentage Pharma Group International American Depository Shares
AAPG stock →Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation.
Health Care · Biotechnology: Pharmaceutical Preparations · 828 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
AAPG vs OMER FAQ
Which is bigger, Ascentage Pharma Group International American Depository Shares or Omeros?
Omeros (OMER) is larger, with a market capitalization of $1.38B compared with $1.36B for Ascentage Pharma Group International American Depository Shares (AAPG).
Which stock has performed better over the past year, AAPG or OMER?
OMER returned +335.54% over the past 12 months, compared with -63.83% for AAPG (price return, excluding dividends). Past performance does not predict future results.
Are Ascentage Pharma Group International American Depository Shares and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.